News - 29 May `23Data-Driven Drug Development in Vitiligo

New

In an interview with Dermatology Times, Stefan Weiss, MD from OM1, a data analytics company, highlighted how leveraging large-scale data analytics can enhance dermatological care, especially for conditions like vitiligo. By creating detailed datasets, OM1 aims to personalize treatment, ensuring patients receive the most effective drugs for their specific conditions. This method promises improved outcomes by analyzing diverse patient responses.

Their study, presented at the ISPOR Annual Conference in Boston, utilized the OM1 Dermatology Network to examine vitiligo's impact, exploring demographics, mental health, and treatment trends in 26,016 patients, based on healthcare claims and patient records from 2013 to 2022. Findings reveal a majority female demographic, diverse racial composition, and common use of treatments like corticosteroids and UVB phototherapy. 

Download poster "Patient Characteristics and Social Determinants of Health in a Large Real-World Cohort of Vitiligo Patients in the U.S." in full size here below. 

 

 



    FAQOther Questions

    • Isn't it just a cosmetic disorder?

      Contrary to popular belief, vitiligo is not merely a cosmetic issue but a complex autoimmune disorder that affects the body’s largest organ—along with other vital systems—and is...

    • PTSD in Vitiligo?

      Living with vitiligo often involves more than managing visible skin changes. Many individuals face discrimination, social stigma, and feelings of isolation, leading to emotional...

    • Is there a link between vitiligo and depression?

      Depression and anxiety are often linked with vitiligo, significantly impacting a person’s quality of life. The connection stems from the shared origin of the skin and brain duri...